What caused the CEE Healthcare fund to plunge

The poor performance of the fund is directly related to the long position stocks. Second-quarter data show that the largest fund size of China Europe medical health mix A, China Europe medical health mix C, the two "China Europe medical fund" top ten long positions include Aier ophthalmology, WuXi Kangde, Tongze medical, Kelaiying, Kanglong Chemical, Taige medicine, Zhifei Biological, Changchun High-tech, Boteng shares and other companies. From the recent three-month stock price performance, these ten long positions in the company, only four companies rose positive, the remaining six companies are down. The worst is Changchun High-tech, the last three months fell as much as 48.62%.

1. Aier Ophthalmology: the main eye hospital investment and hospital operation and management services, (shall not be engaged in the absorption of deposits, fund-raising collection, entrusted loans, the issuance of notes, the issuance of loans and other national financial regulation and financial credit business).

2. WuXi PharmaTech: Wuxi WuXi PharmaTech New Drug Development Co., Ltd. was established in December 2000, is a global leader in pharmaceutical, biotechnology, and medical device research and development of open-ended capabilities and technology platforms companies.

3. Tongze Medical: Tongze Medical Co., Ltd (stock code: 600763SH) is a listed company on the main board with medical services as its main business. The company currently owns a number of oral healthcare and health and reproductive healthcare organizations, and is committed to becoming China's leading integrated healthcare platform.

4. Kaleiden: Kaleiden Pharmaceutical Group (Tianjin) Co., Ltd (stock code: 002821.SZ) is a leading global CDMO company, providing high-quality one-stop service for the research, development, and production of new drugs worldwide. Taking accelerating the launch of new drugs and prolonging the quality of life as its mission, relying on continuous technological innovation, it provides one-stop CMC services for the whole life cycle of drugs for domestic and foreign pharmaceutical and biotechnology companies to accelerate the development and application of new drugs.

5. Kanglong Huacheng: Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. provides global pharmaceutical companies, biotechnology research and development companies and research institutes with integrated drug research, development and manufacturing CRMO solutions spanning the two phases of drug discovery and drug development, and is committed to helping its partners to achieve success in the discovery, development and commercialization of new drugs.

6. Tigermed: Hangzhou Tigermed Technology Co., Ltd (stock code: 300347.SZ/3347.HK) is an industry-leading integrated biopharmaceutical R&D service platform that provides innovative solutions for clinical research across the full cycle for the global pharmaceutical and medical device industries.

7. Zhifei Biotechnology: Zhifei Biotechnology is a biological high-tech enterprise integrating the research and development, production, promotion, sales, distribution, import and export of vaccines and biological products, and its main human vaccine is one of the seven strategic emerging industries with a promising development prospect.

8. Changchun High-Tech: The company's main business is the research and development, production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development, property management and real estate leasing and other businesses. After years of industrial layout and R&D investment, the company's pharmaceutical products cover a number of pharmaceutical segments such as innovative genetic engineering pharmaceuticals, new vaccines, and modern Chinese medicine, which is the main source of the company's performance.

9. Boten: The company mainly provides global pharmaceutical companies, new drug R&D organizations, etc. with customized R&D and production services of chemical drugs, biological drugs and preparations required for the whole life cycle from early clinical research to drug launch.